Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.62 |
| ▸ | CA2 | P00918 | 3/20 | 0.62 |
| ▸ | CA7 | P43166 | 3/20 | 0.62 |
| ▸ | CA9 | Q16790 | 3/20 | 0.62 |
| ▸ | KDR | P35968 | 3/20 | 0.58 |
| ▸ | TEK | Q02763 | 1/20 | 0.58 |
| ▸ | NAMPT | P43490 | 1/20 | 0.51 |
| ▸ | RAF1 | P04049 | 2/20 | 0.49 |
| ▸ | CASR | P41180 | 1/20 | 0.48 |
| ▸ | ABL1 | P00519 | 2/20 | 0.48 |
| ▸ | BCR | P11274 | 2/20 | 0.48 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.48 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1789919 | 0.91 | CA1 (0.63) | CA1CA2CA7CA9KDR | |
| SCHEMBL1790350 | 0.90 | CA1 (0.53) | CA1CA2CA7CA9KDR | |
| SCHEMBL1791365 | 0.89 | CA1 (0.61) | CA1CA2CA7CA9KDR | |
| SCHEMBL1790433 | 0.89 | CA1 (0.64) | CA1CA2CA7CA9KDR | |
| SCHEMBL1792584 | 0.88 | CA1 (0.65) | CA1CA2CA7CA9KDR | |
| SCHEMBL15677923 | 0.88 | CA1 (0.62) | CA1CA2CA7CA9KDR | |
| SCHEMBL1789524 | 0.86 | CA1 (0.58) | CA1CA2CA7CA9KDR | |
| SCHEMBL1791201 | 0.85 | CA1 (0.64) | CA1CA2CA7CA9KDR | |
| SCHEMBL1792474 | 0.85 | CA1 (0.59) | CA1CA2CA7CA9KDR | |
| SCHEMBL1790420 | 0.85 | CA1 (0.67) | CA1CA2CA7CA9KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663204-B1 | C-KIT MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2014-05-07 | — | — | EP | claimed |
| US-8362017-B2 | N-[5-chloro-2-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide; antiproliferative agents; protein kinase inhibitors; drug screening | EXELIXIS, INC. (US) | 2013-01-29 | — | — | US | claimed |
| US-20080096892-A1 | C-Kit Modulators And Methods Of Use | EXELIXIS, INC. (US) | 2008-04-24 | — | — | US | claimed |
| EP-2139484-B9 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF PI3K ALPHA | EXELIXIS INC (US) | 2014-06-11 | — | — | EP | disclosed |
| EP-2139483-B9 | COMBINATION THERAPIES COMPRISING A QUINOXALINE INHIBITOR OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS INC (US) | 2014-05-21 | — | — | EP | disclosed |
| EP-1663204-B1 | C-KIT MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2014-05-07 | — | — | EP | disclosed |
| EP-1663204-B1 | C-KIT MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2014-05-07 | — | — | EP | disclosed |
| EP-2139483-B1 | COMBINATION THERAPIES COMPRISING A QUINOXALINE INHIBITOR OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS INC (US) | 2013-09-18 | — | — | EP | disclosed |
| US-8513266-B2 | Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K alpha | EXELIXIS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8481001-B2 | Combination therapies comprising quinoxaline inhibitors of P13K-alpha for use in the treatment of cancer | EXELIXIS, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-8362017-B2 | N-[5-chloro-2-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide; antiproliferative agents; protein kinase inhibitors; drug screening | EXELIXIS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362017-B2 | N-[5-chloro-2-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide; antiproliferative agents; protein kinase inhibitors; drug screening | EXELIXIS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362017-B2 | N-[5-chloro-2-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide; antiproliferative agents; protein kinase inhibitors; drug screening | EXELIXIS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20110123434-A1 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF P13K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS, INC (US) | 2011-05-26 | — | — | US | disclosed |
| US-20100209420-A1 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF P13K ALPHA | EXELIXIS, INC. (US) | 2010-08-19 | — | — | US | disclosed |
| US-20080096892-A1 | C-Kit Modulators And Methods Of Use | EXELIXIS, INC. (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080096892-A1 | C-Kit Modulators And Methods Of Use | EXELIXIS, INC. (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080096892-A1 | C-Kit Modulators And Methods Of Use | EXELIXIS, INC. (US) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096892-A1 | C-Kit Modulators And Methods Of Use | KIT, PRKCH, PRKCB | CA1 2225/4885CA2 1236/4885CA7 1237/4885 |
| US-20100209420-A1 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF P13K ALPHA | TP53, PHKG1, TNNI3K | CA1 1802/4885CA2 1918/4885CA7 1790/4885 |
| US-20110123434-A1 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF P13K-ALPHA FOR USE IN THE TREATMENT OF CANCER | TP53, PHKG1, TNNI3K | CA1 1644/4885CA2 1519/4885CA7 1230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.